Global Strontium-89 Chloride Injection Market Research Report 2024
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Strontium-89 Chloride Injection Market Research Report 2024
Strontium-89 chloride is in a class of drugs known as radioisotopes. It delivers radiation to cancer sites and ultimately decreases bone pain. Strontium chloride Sr 89 is a radiopharmaceutical. Strontium chloride Sr 89 is used to help relieve the bone pain that may occur with certain kinds of cancer. The radioactive strontium is taken up in the bone cancer area and gives off radiation that helps provide relief of pain. Strontium chloride Sr 89 is to be given only by or under the direct supervision of a doctor with specialized training in nuclear medicine or radiation oncology.
According to Mr Accuracy reports’s new survey, global Strontium-89 Chloride Injection market is projected to reach US$ 138.1 million in 2029, increasing from US$ 84 million in 2022, with the CAGR of 7.2% during the period of 2024 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Strontium-89 Chloride Injection market research.
Strontium chloride [89Sr] injection has good bone affinity. After intravenous injection into the human body, it can gather at high concentrations in bone metastases, emit β-rays, and directly act on tumor cells. It can relieve pain caused by various bone metastases Significant curative effect. One injection can treat all the lesions in the body, make them shrink or disappear, and it is an effective therapy for pain relief of bone metastases, so it has received widespread attention worldwide, especially in China.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Strontium-89 Chloride Injection market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.

Q BioMed
Bio Nucleonics Inc
Yantai Dongcheng Biochemicals Co.,Ltd.
Hta Co., Ltd
Chengdu Gaotong Isotope Co.,Ltd.
Jaco Pharmaceuticals Co,ltd
Segment by Type
111 MBq
148 MBq
222 MBq
296 MBq
Hospital
Cancer Center
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
The Strontium-89 Chloride Injection report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Manufacturers’ Competition Patterns
Chapter 3Country Level Sales Analysis
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6Manufacturers’ Outline
Chapter 7Industry Chain, Market Channel and Customer Analysis
Chapter 8Market Opportunities and Challenges
Chapter 9Market Conclusions
Chapter 10Research Methodology and Data Source
According to Mr Accuracy reports’s new survey, global Strontium-89 Chloride Injection market is projected to reach US$ 138.1 million in 2029, increasing from US$ 84 million in 2022, with the CAGR of 7.2% during the period of 2024 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Strontium-89 Chloride Injection market research.
Strontium chloride [89Sr] injection has good bone affinity. After intravenous injection into the human body, it can gather at high concentrations in bone metastases, emit β-rays, and directly act on tumor cells. It can relieve pain caused by various bone metastases Significant curative effect. One injection can treat all the lesions in the body, make them shrink or disappear, and it is an effective therapy for pain relief of bone metastases, so it has received widespread attention worldwide, especially in China.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Strontium-89 Chloride Injection market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.

By Company
Q BioMed
Bio Nucleonics Inc
Yantai Dongcheng Biochemicals Co.,Ltd.
Hta Co., Ltd
Chengdu Gaotong Isotope Co.,Ltd.
Jaco Pharmaceuticals Co,ltd
Segment by Type
111 MBq
148 MBq
222 MBq
296 MBq
Segment by Application
Hospital
Cancer Center
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
The Strontium-89 Chloride Injection report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Manufacturers’ Competition Patterns
Chapter 3Country Level Sales Analysis
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6Manufacturers’ Outline
Chapter 7Industry Chain, Market Channel and Customer Analysis
Chapter 8Market Opportunities and Challenges
Chapter 9Market Conclusions
Chapter 10Research Methodology and Data Source
